Audit: QRS - Vitamin K2 (MK-4 & MK-7) for Health & Longevity
Audit conducted on 11/08/2026 06:18 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every populated span traces to ER text: protocol cells to Therapeutic Protocol (ER 370–386), time cells to Practical Considerations “Time to effect” (ER 430), benefit/risk tiers to the ER sub-headings, gates to Key Interactions & Contraindications (ER 318–346), markers and cadence to the Monitoring Protocol & Defining Success table and paragraph (ER 460–478). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious verdict wording is carried through verbatim, e.g. “no interaction” for direct oral anticoagulants and “monitor”/”caution” tags (QRS 589–612) match ER 318–338; “not applicable otherwise” retained in marker_5_target (QRS 719). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindication strength is preserved — pregnancy/breastfeeding at pharmacological MK-4 doses stays a stop item (QRS 577), and the vitamin K antagonist gate keeps its “unless a clinician sets a fixed dose” condition (QRS 570–571). |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | No content from ER Benefit-Modifying Factors (ER 234–246) or Risk-Modifying Factors (ER 302–312) appears in the gates, benefits, or risks cards; each QRS block draws from its own mapped ER section. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no PMIDs, author names, NCT identifiers, or brand names; the ER’s “Eisai’s Glakay” (ER 372) was correctly dropped from action_2_sub. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind appear in the sheet. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, evidence-graded register matching the ER, including the ER’s own plain-language Conclusion phrasing reused in at_a_glance. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets and doses sit alongside plain-language framing; the sheet states what is known and what is unsettled without discouraging language. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated descriptively (“Absorption, not timing, drives the recommendation”, QRS 485) rather than as instructions to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Gates and markers are framed as conditions and readouts; the only advisory sentence is the fixed template disclaimer (QRS 816–818). |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No imperative or advisory constructions in the document’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Marker names are spelled out in full rather than abbreviated (e.g., “Dephosphorylated-uncarboxylated matrix Gla protein”, QRS 660; “Estimated glomerular filtration rate”, QRS 759). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Benefits and risks are reduced to tier-tagged clause lists; the twelve-bullet ER protocol is reduced to three action cells. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-file check for “you”/”your”; none present. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Biomarker targets, dose ranges, and structural endpoints assume an actively self-managing reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Thrice-daily 15 mg MK-4 dosing (QRS 471) and specialist-assay monitoring are presented without hedging about inconvenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Research-grade markers such as dephosphorylated-uncarboxylated matrix Gla protein and coronary artery calcium scoring are presented as routine, which is not a general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | at_a_glance foregrounds the evidence gradient and the anticoagulant conflict, the two decision-relevant points for this audience (QRS 434–438). |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur; the title uses “Health & Longevity” (QRS 417). |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal terminology throughout; the plain-language wording in at_a_glance (“blood-thinning drugs”) is taken from the ER Conclusion (ER 506) and is required there by item 7.4. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings match the template byte for byte (QRS 446, 491, 533, 566, 586, 622, 647, 784, 651–653) including the template’s unescaped ampersand in “Risk & Side Effects”. |
| 3.2 | All <span data-qrs-var="NAME">...</span> from the [qrs_template] are present in the the QRS. |
🟢 | All 34 distinct template variables are present; the repeated marker_#_* and qualitative_item_# rows expand to 8 and 4 instances, giving 62 spans total. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three non-variable spans website="evidence_review", website="audit", and website="full_review" are unchanged (QRS 423, 426, 440). |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section mapped into the QRS is empty; every benefit tier, risk tier, gate list, protocol, monitoring, and qualitative block has ER content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | All eleven caution labels reproduce the ER bold labels verbatim including their parenthetical drug lists (QRS 589–612 vs ER 318–338); action labels match ER 370, 372, 378. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect cell labels are drawn from the ER’s own wording in the single “Time to effect” bullet — “carboxylation markers”, “Bone density”, “arterial stiffness” (ER 430). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters occur in the file; the ER’s 🟩/🟥/🟨/⚠️ markers were all stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section with latitude was condensed: benefits and risks reduced to bare tier headings, the twelve-bullet ER protocol to three cells, contraindications stripped of their definitional glosses, and the two-paragraph cadence text to one sentence. The remaining length is carried by content that other items require verbatim (4.2, 9.5, 14.2). |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Comment opens at QRS line 2, immediately after <!doctype html> on line 1, and closes at line 14 before the template comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3 and closing --- at line 13; the “QRS — Metadata” caption on line 2 precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; none of its values are echoed by a rendered element other than the independently required header date and model. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because it contains a colon; all other values are bare and untrimmed of nothing. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: vitamin_k2_mk_4_mk_7_2026-0811-0321_Opus_ER.md (QRS 4) matches the ER’s own filename field (ER 17). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02 (QRS 5) matches the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0811-0609 (QRS 6) is in the required format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus (QRS 7). |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 (QRS 8). |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version with no trailing qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: vitamin_k2_mk_4_mk_7_2026-0811-0321_Opus_QRS.html (QRS 9) matches the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all ten keys; formatting is consistent and no stray quoting or padding is present. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “Vitamin K2 (MK-4 & MK-7) for Health & Longevity - Quick Reference Sheet” (QRS 22) matches canonical_topic (ER 8) with both ampersands encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | “Vitamin K2 (MK-4 & MK-7) for Health & Longevity” (QRS 417). |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0811-0609 renders as “08/11/2026” (QRS 421). |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 5” (QRS 425) matches the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block (QRS 415–428) is the template subline only; the ER’s “Also known as” list (ER 30) was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses all three Conclusion paragraphs (ER 502–506) into what the compound is, how the evidence grades out, and the one decision-blocking conflict. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 58 words (QRS 434–438). |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | “beyond dispute”, “well supported”, “genuinely unsettled”, and “rests entirely on population studies” map one-to-one onto ER 504; the tolerability and anticoagulant clauses map onto ER 506. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “artery hardening” and “blood-thinning drugs” stand in for calcification and vitamin K antagonists. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, or sample sizes appear. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric results; the ER’s magnitudes were all left out. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Sourced from the “Populations who should avoid Vitamin K2 (MK-4 & MK-7)” list at ER 340–346. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER populations are present and none was added (QRS 569–581). |
| 8.3 | Individual [stop_items] are formatted as <li></li> |
🟢 | Five discrete <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing rationale stripped: “where safety data are absent” (ER 345) and the “a measure of kidney filtering capacity” gloss (ER 346) are both gone; no dash-trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(time in therapeutic range below 60%)”, “(above 1 mg daily)”, and “(estimated glomerular filtration rate under 30 mL/min/1.73 m²)” are all retained (QRS 574, 577, 579–580). |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s contraindication parentheticals contain no ranking notation; they carry only thresholds and dose values. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names five such populations, and the section is correspondingly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no population that should avoid the intervention --> |
N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Sourced from the eleven interaction bullets at ER 318–338. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eleven interactions are carried; none duplicates a stop item, whose entries are population-scoped (mechanical heart valve, unstable INR) rather than the interaction itself. |
| 9.3 | Individual [caution_items] are formatted as <li></li> |
🟢 | Eleven discrete <li> elements inside the caution_items span (QRS 589–612). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item is reduced to label plus verdict; every mechanistic sentence and mitigation instruction from ER 318–338 (e.g., “Dosing is separated by at least four hours”) was stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All parenthetical drug lists and effect qualifiers are retained intact, including “(apixaban, rivaroxaban, dabigatran, edoxaban)” and “(additive effect on clotting)”. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction parentheticals are already plain comma-separated lists with no ranking symbols. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names eleven interactions, and the section is correspondingly populated rather than empty. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no interaction that changes how the intervention is used --> |
N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to the ER Therapeutic Protocol section (ER 368–392). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The two dosing regimens that define the intervention (ER 370, 372) plus administration timing (ER 378); the remaining nine bullets are refinements to those three. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies twelve protocol bullets, so all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | Nine of nine spans populated; e.g. action_1 “Low-dose MK-7 approach / 100–200 µg daily / All-trans MK-7, once daily. 180 µg carries the strongest three-year outcome data.” draws on ER 370 and ER 382. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Carboxylation markers, bone density, and arterial stiffness are exactly the three latencies the ER gives (ER 430). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Order follows the ER benefit tiers: carboxylation restoration and bone density are both High (ER 168, 174), arterial elasticity is Medium (ER 188). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct latencies, so all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Nine of nine spans populated with the ER’s own values — 2–4 weeks with an 8–12 week plateau, and 2–3 years for both structural endpoints (QRS 497–526). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information (ER 430), so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All four tiers map to the ER Expected Benefits sub-headings (ER 166–228). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated (QRS 535–559). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a bare semicolon-separated list of ER sub-headings; every “Magnitude:” line, trial reference, and “⚠️ Conflicted” qualifier was dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain in any benefits span. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. |
N/A | All four ER benefit tiers contain items, so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All four tiers map to the ER sub-headings at ER 254–296. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated (QRS 624–641). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Reduced to ER sub-heading text; the INR mechanism, pooled risk ratios, and “⚠️ Conflicted” marker on breast cancer risk were all dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain in any risks span. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. |
N/A | All four ER risk tiers contain items, so no span needed hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Marker names, targets, and “Why” text are taken from the ER Monitoring Protocol & Defining Success table (ER 462–471). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER table rows appear as marker_1 through marker_8, in ER order, with the “Optimal Functional Range” and “Why Measure It?” values preserved. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Populated (QRS 774–778) with the 3-month/12-month marker recheck, 2-year bone scan, 3–5 year calcium score, and weekly INR schedule from ER 460. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Taken from the “Qualitative markers worth tracking alongside the laboratory set” list at ER 473–478. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All four ER qualitative markers appear as qualitative_item_1 through qualitative_item_4 (QRS 786–808). |
Issues 11/08/2026 06:18
Pass rate 100.00%. No issues found.